August 22, 2025, Cleveland, OH – Researchers at the Cleveland Clinic have demonstrated the power of an artificial intelligence-powered precision treatment system in managing type 2 diabetes in a seminal study.
Published in NEJM Catalyst, the study shows major glycemic improvements and reduced medication use with the Twin Precision Treatment system.
The randomized clinical trial had 150 patients, 100 treated with the AI intervention and 50 with standard care. Among the AI group at 12 months, 71% had an A1C value below 6.5% on metformin alone, compared with only 2.4% of the standard care group.
Health Technology Insights: Meghan Geary Named SVP of Operations at MedX Health
The AI group patients also lost 8.6% body weight on average, nearly double that of the 4.6% of the control group. The use of expensive medication, including GLP-1 receptor agonists and insulin, was also drastically cut in the AI group.
The Twin Precision Treatment system, created by Twin Health, integrates wearable sensors, continuous glucose monitoring, and AI-driven analytics to provide personalized health insights and lifestyle advice. The system also includes human telecoaching, delivering real-time recommendations to the patients.
AI has the potential to revolutionize diabetes care, according to study senior author Dr. Kevin Pantalone, Director of Diabetes Initiatives at the Cleveland Clinic. “This study demonstrates that AI can deliver individualized, real-time interventions that actually make a difference in terms of enhancing outcomes for patients,” he stated.
The findings indicate AI precision treatment could become central in diabetes care, providing scalable, cost-effective solutions for better patient outcomes.
Health Technology Insights: Develop Health Raises $14.3Million to Automate Prior Authorization
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
